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Abstract
Background: Peripheral arterial disease (PAD) is generally associated with considerable morbidity and reduced
quality of life. Patient-reported outcome measures (PROMs) provide important information about the burden of
disease and impact of treatment in affected patients.
Objectives: The objective of the review was to identify and appraise studies reporting the psychometric evaluation of
PROMs administered to a specified population of patients with PAD with a view to recommending suitable PROMs.
Methods: A systematic review of peer-reviewed English language articles was undertaken to identify primary studies
reporting psychometric properties of PROMs in English-speaking patients with various stages of PAD. Comprehensive
searches were completed up until January 2015. Study selection, data extraction and quality assessment were
undertaken independently by at least two researchers. Findings were presented as tabular and narrative summaries
based on accepted guidance.
Results: Psychometric evaluation of 6 generic and 7 condition-specific PROMs reported in 14 studies contributed data
to the review. The frequently reported measure was the SF-36 (n = 11 studies); others included the Walking Impairment
Questionnaire (n = 8 studies), EQ-5D (n = 5 studies) and the Vascular Quality of Life Questionnaire (n = 3 studies).
Studies included a diverse PAD population and varied in methodology, including approach to validation of PROMs.
Conclusions: Various PROMs have been validated in patients with PAD but no study provided evidence of a full
psychometric evaluation in the patient population. Careful selection is required to identify reliable and valid PROMs to
use in clinical and research settings.
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Background
Patient-reported outcome measures (PROMs) reflect pa-
tients’ perspectives on their health status, functioning
and quality of life (QoL) [1] and are also useful for
informing clinical and healthcare decision-making [2].
Since April 2009, the National Health Service (NHS) in
England requires patients undergoing surgery to provide
PROMs data before and after treatment. The current
PROMs programme covers patients undergoing varicose
vein, groin hernia, knee replacement and hip replace-
ment surgery [3]. Presently, PROMs are not routinely
collected for patients with peripheral arterial disease
(PAD), a condition associated with substantial disability,
morbidity and mortality [4]. PAD is caused by wide-
spread atherosclerosis of the lower limbs and may be
asymptomatic in the early stages. An initial common
presentation of PAD is atypical leg pain. Pain may occur
in a specific group of muscles in the lower limb during
effort (this is referred to as intermittent claudication).
Severe stages of PAD present as rest pain in the legs, leg
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ulcers or gangrene—collectively known as critical limb
ischaemia (CLI). The mainstay of treatment is to im-
prove symptoms, delay disease progression, prevent tis-
sue loss and modify risk factors [4, 5].
Validation studies provide valuable evidence for selecting
appropriate PROMs for use in clinical and research settings.
In this review, the term validation study refers to a study
reporting the evaluation of one or more measurement
properties of a PROM—including its validity (the degree to
which the instrument measures what it is supposed to
measure); reliability (the degree to which measures are
reproducible and consistent over time in patients with a
stable condition); responsiveness (the degree to which the
instrument detects meaningful change over time) and
acceptability (the degree to which the instrument is accept-
able to the patient). A suitable PROM must demonstrate its
validity, reliability, responsiveness and appropriateness in a
relevant patient population [6]. Confirmation of these psy-
chometric properties must be obtained from sources (i.e.
context of study, patient factors and study characteristics)
similar to those in which the PROMs will be applied [6].
A better understanding of the psychometric properties of
PROMs obtained from English-speaking patients with PAD
will help to select an appropriate tool for patients managed
within the NHS. Therefore, this study sought to (1) identify
English language publications reporting the psychometric
evaluation of PROMs in patients with PAD, (2) critically
appraise eligible studies, and (3) examine the psychometric
properties of identified PROMs to inform the development
of a valid and reliable instrument to incorporate into an
electronic personal assessment questionnaire (ePAQ) as
part of a project to inform the reconfiguration of vascular
services in the UK..
Methods
A systematic review of peer-reviewed English language arti-
cles was undertaken according to recommendations of the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) group [7], the Oxford system and the
Consensus-based Standards for the selection of health
Measurement Instruments (COSMIN) group [8, 9] with the
aim to identify validation studies in a well-defined population
of English-speaking patients with symptomatic PAD. The
study’s protocol is available on request from the authors.
Literature searches
Comprehensive searches using a two-staged approach were
conducted in Medline and Medline in Process, EMBASE,
the Cochrane Library, CINAHL, PsycINFO and Web of Sci-
ence from date of inception up to August 2013 (Search 1)
and up to February 2014 (Search 2). Updated searches were
conducted in Medline and Medline in Process in January
2015. Search 1 sought to identify studies reporting PROMs
in patients with PAD while Search 2 aimed to identify
studies reporting the development and/or validation of
relevant PROMs. Relevant PROM terms were identified
from scoping searches, discussions with experts and previ-
ous research relating to relevant outcome measures. Search
terms in the search 1 strategy included free text terms and
Medical Subject Heading (MeSH) terms related to: (1) PAD;
(2) known generic PROMs and (3) known condition-
specific PROMs. Additional PROMs were identified follow-
ing examination of titles and abstracts of records retrieved
from Search 1. All potentially relevant articles were also
coded at this stage. The search 2 strategy comprised of all
terms used in the search 1, together with (1) additional
PROM terms identified from sifting retrieved records and
(2) a methodological search filter for locating studies report-
ing measurement properties. Search strategies were adapted
for searching within different databases. Search strategies
used in Medline are available as Additional file 1.
Further searches were conducted in the PROMs Bib-
liography (Oxford University) and the Patient-Reported
Outcome and Quality of Life Instruments database (PRO-
QOLID) [10]. References of identified systematic reviews
and included studies were examined for potentially eligible
studies. All retrieved records were transferred and man-
aged within a single reference management database.
Study selection
Study selection was undertaken by one reviewer from a
pool of 4 reviewers (EP, ME, PP, RD) and checked by a sec-
ond reviewer. Eligibility criteria are summarised in Table 1.
Disagreements were resolved by discussion and referred to
a third reviewer, when needed. After excluding duplicates
and records which did not appear to be relevant by examin-
ation of titles and abstracts, all full-text articles of poten-
tially relevant articles were obtained for detailed review.
Studies including English-speaking patients with a diag-
nosis of PAD were included in the review. Proficiency in
English was indicated or assumed if studies were conducted
in countries where English is an official language and/or re-
ported that 80% or more of participants were English
speakers. Studies published in English but reporting out-
comes obtained from translated instruments, i.e. non-
English translations of relevant PROM instruments or Eng-
lish versions of non-English PROMs were excluded. This
was considered as an acceptable approach to overcome the
uncertainty due to language validation and cross-cultural
adaptation of PROMs [11].
Data extraction
Data extraction was completed by one author (either EP,
ME, PP, RD or AK) and checked by another author. All
disagreements were discussed and resolved by consensus.
Data were abstracted into a piloted standardised form and
comprised patient characteristics, study characteristics,
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names, domains, items and reported psychometric evalua-
tions of identified PROMs.
Quality assessment
The methodological quality of studies was assessed using
the COSMIN checklist [12]. This checklist comprises of
114 items organised as 12 boxes related to the following
measurement properties: validity (including structural
validity, content validity, criterion validity and cross-
cultural validity), internal consistency, reliability, meas-
urement error, responsiveness and hypothesis-testing. A
4-point rating scale (excellent, good, fair or poor) was
applied with the overall methodological quality scores
presented using a “worst score counts method” per box
[13]. The COSMIN checklist also covers interpretability
and generalisability which were assessed but not scored.
Due to the lack of consensus on how to appraise PROMs,
study-specific criteria were adapted from various sources
[2, 8, 14–17] as outlined in Table 2 and used for the assess-
ment of psychometric performance of identified PROMs.
Data synthesis and analysis
Tabular and narrative syntheses of study characteristics
were undertaken. A summary of psychometric criteria was
completed based on the Oxford system and the COSMIN
group system [8, 9]. The following combined rating scales
were allocated: (0) for not reported; (−) for evidence not
in favour; (+/−) for conflicting evidence; (?) for question-
able methodology and (+) for evidence in favour.
Results
Of the 6893 records retrieved from searches, 14 studies
with data for 13 PROMs were found to be eligible to be
included in this review as shown in Fig. 1. Twenty-eight
full-text articles were excluded because they reported
outcomes using ‘non-eligible’ PROMs (i.e. English trans-
lations of non-English PROMs and non-English versions
of relevant PROMs), included study populations for
whom outcomes were not clearly reported or presented
no data on psychometric evaluations.
Study characteristics
Table 3 provides a summary of study characteristics.
Studies were conducted in Australia [18], UK [19–25]
and the USA [26–31]. All studies were conducted as
prospective observational studies. Missing information
relating to study setting [22, 30, 31], diagnostic criteria
of participants [18, 24, 26, 28, 30, 31] and schedule for
assessment of PROMs was noted.
Participants’ characteristics
Data were available for 1594 patients presenting with symp-
tomatic PAD. Sample sizes ranged from 26 to 295 patients
with more than 50% of included studies reporting study
populations of less than 100 participants. Overall, men
made up between 54 [22] and 91% [27] of study popula-
tions. Diagnostic criteria and management strategies varied
across studies. Included studies fell into 2 broad categories
based on diagnosis of patients: studies with (i) patients with
IC only [18, 20, 22, 24, 27, 29] or (ii) patients with different
degrees of severity of PAD [19, 21, 23, 26, 28, 30, 31].
Psychometric data
Data relating to the psychometric evaluation of 6 generic
PROMs and 7 condition-specific PROMs in patients with
PAD were available. The most frequently assessed generic
Table 1 Criteria for considering eligibility of studies for inclusion in the review
Inclusion criteria Exclusion criteria
Population Defined population of English-speaking
participants aged 18 years (adults) with PADa
Patients with rest pain; claudication; vascular
spasms; ischaemic ulceration; amputation;
necrosis or gangrene of the limb due to PAD
Undefined population or Non-English
speaking adults with PAD
Patients with rest pain; claudication;
vascular spasms; ischaemic ulceration;
amputation; necrosis or gangrene
of the limb due to any cause other than PAD
Interventions No intervention or any intervention indicated for PAD Intervention, not intended for the management of PAD
Outcomes Original version of PROMs in English including
• generic or preference-based measures e.g.
EQ-5D, SF-6D, SF-36;
• directly elicited preference-based measures e.g.
time-trade-off (TTO), standard gamble (SG)
utility values; condition-specific outcome measures;
• functional outcome measures
Original version of PROMs in English including
• Outcome measures of patient satisfaction or experience
• Outcome measures obtained from proxies,
carers or health providers
Non-English versions of PROMs
English translations of non-English PROMs
Study type Validation studies of a relevant PROM addressing
• Validity;
• Reliability;
• Responsiveness or acceptability
Publication in English
Studies of linguistic validation of PROMs
Review articles, letters, commentaries, abstracts
Non-English publications
Unpublished studies
Abbreviations: EQ-5D EuroQoL-5D, PAD peripheral arterial disease, PROM patient-reported outcome measure, SF-6D 6-item shortened version of SF-36, SF-36
Medical Outcomes Study 36-item short form health survey, SG standard gamble, TTO time trade-off
aOther descriptions considered included peripheral vascular disease; peripheral obliterative arteriopathy; peripheral arterial occlusive disease
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questionnaires were the SF-36 [18–23, 26, 27, 30, 31] and
the EQ-5D [19, 20, 22, 26]. The King’s College Hospital
Vascular Quality of Life Questionnaire (VascuQoL) [22, 23,
25] and the Walking Impairment Questionnaire (WIQ) [20,
24, 26–31] were the commonly reported condition-specific
measures. Two studies reported the evaluation of the Clau-
dication Scale (CLAU-S) and the Estimation of Ambulatory
Capacity by History Questionnaire (EACH-Q) which were
originally developed in France [24] and Germany [22], re-
spectively, alongside relevant PROMs. Information relating
to the CLAU-S and EACH-Q was excluded in this review.
Information about the development of the WIQ [29];
Intermittent Claudication Questionnaire (ICQ) [20];
VascuQoL [23]; Peripheral Artery Questionnaire (PAQ)
[30] and the PAD Quality of Life Questionnaire (PAD-
QOL) [31] was found in 5 studies. Limited information
about the development of the WIQ was noted [29],
however for the remaining instruments studies reported
methods consistent with recommended standards [11, 32].
Items, domains, response options and scoring of identified
PROMs are presented in Table 4.
In relation to the COSMIN checklist, the methodo-
logical quality was assessed by totalling the number of
boxes that have been scored from poor to excellent. Of
36.8% of the included studies (n = 42 boxes) was rated as
poor, 40.3% (n = 46 boxes) as fair; 21.9% (n = 25 boxes) as
good and 0.9% (n = 1 boxes) as excellent. Details of quality
assessment are presented in Additional file 2: Table S1.
Assessment of psychometric properties
The timing of assessments of the validity of PROMs varied
across studies and sometimes, within the same study [29].
Data on responsiveness were reported for the WIQ [29],
ICQ [20]; VascuQoL [22, 23]; SF-8 [21]; SF-36 [19, 21–23];
EQ-5D [19, 22]; Nottingham Health Profile (NHP) and
Sickness Impact Profile-intermittent claudication (SIPic)
[22]. Test-retest reliability of PROMs was reported in 8
studies. Follow-up periods varied and ranged from 1-
week [19, 20, 27]; 2-week [20, 21, 26] to 1-month inter-
vals [23, 30]. A summary of reported psychometric
properties of identified PROMs is presented in Table 5.
Generic patient-reported outcome measures
Eleven studies assessed the construct validity of the SF-36.
Five studies [20–23, 30] reported good evidence with the
remaining presenting mixed evidence. Evidence for the in-
ternal consistency of the SF-36 was negative from one study
[18] and positive in another study [30]. Only one study [25]
reported positive evidence on responsiveness while the six
studies [19–23, 30] found mixed evidence. Test-retest reli-
ability was assessed in 4 studies with 2 studies providing evi-
dence in favour of test re-test reliability [18, 30]; one study
[19] describing positive evidence on test-retest reliability
using simple correlations but providing no information on
Table 2 Appraisal criteria for assessing the psychometric
properties of patient reported outcome measures
Domain Criteria
Test re-test reliability Reliability is the ability of a measure to reproduce
the same value on two separate administrations
when there has been no change in health.
The intra-class correlation/ weighted kappa score
should be≥ 0.70 for group comparisons and
≥ 0.90 if scores are going to be used for
decisions about an individual based on their
score [2].
The mean difference (paired t test or Wilcoxon
signed-rank test) between time point 1 (T1) and
time point 2 (T2) and the 95% CI should also
be reported.
Internal consistency Internal consistency is an assessment of whether
the items are measuring the same thing.
A Cronbach’s alpha score of≥ 0.70 is considered
good and it should not exceed ≥0.92 for group
comparisons as this is taken to indicate that items
in the scale could be redundant. Item total
correlations should be ≥0.20 [14].
Content validity Content validity measures the extent to which the
items reflect the domains of interest in a way that
is clear.
To achieve good content validity, there must be
evidence that the instrument has been developed
by consulting patients, experts as well as
undertaking a literature review.
Patients should be involved in the development
stage and item generation. The opinion of patient
representatives should be sought on the
constructed scale [2, 14, 16].
Construct validity Construct validity assesses how well an instrument
measures what it was intended to measure.
A correlation coefficient of ≥0.60 is considered as
strong evidence of construct validity. Authors
should make specific directional hypotheses and
estimate the strength of correlation before
testing [2, 14, 15].
Criterion validity Criterion validity assesses the degree of empirical
association of the PROM with external criteria or
other measures.
A good argument should be made as to why an
instrument is a gold standard and correlation
with the gold standard should be≥ 0.70 [15].
Responsiveness Responsiveness assesses the ability of the PROM to
detect changes when changes are expected.
Available methods to measure responsiveness
include t-tests, effect size, standardised response
means or responsiveness statistics, Guyatts’
responsiveness index. Standardised effects sizes
and SRMs of less than 0.2 are considered small,
0.5 moderate, and 0.8 [17].
There should be statistically significant changes
in score of an expected magnitude [8].
Floor-ceiling effects A floor or celling effect is considered if 15% of
respondents are achieving the lowest or the
highest score on the instrument, respectively [15].
Acceptability Acceptability is reflected by the completeness of
the data supplied. 80% or more of the data
should be complete [16].
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time interval for the administration of the measures and the
remaining study [21] assessing reliability using Spearman
correlations instead of intra-class correlation coefficients.
Positive evidence for construct validity and mixed evi-
dence of responsiveness of the SF-8 were reported [21].
One study provided mixed evidence for construct validity
and positive evidence for responsiveness of the SF-6D [25].
The quality of study methodology was shown to be good
for construct validity, mixed for test-re-test reliability, and
poor for responsiveness.
Of the 5 studies evaluating the EQ-5D, one study
showed positive evidence for construct validity [25]; 2
studies reported mixed evidence [19, 26] whereas the
remaining studies [20, 22] had poor methodologies, sub-
sequently limiting further assessment.
The responsiveness of the NHP was found to be
favourable but construct validity and floor/ceiling effects
were associated with mixed evidence [19]. For examining
construct validity of the Profile of Mood States (POMS),
no prior hypotheses of the strength and direction that the
POMS would be related to other measures was reported
[31]. However, the results presented showed statistically
significant correlations with the PADQOL factors [31].
Condition-specific patient-reported outcome measures
Three papers evaluating the VascuQol provided good evi-
dence for its construct validity and responsiveness [22, 23,
25]. Content validity and internal consistency were found
to be positive in the one study [23] with some evidence in
favour of the test-re-test reliability [23]. Evidence for in-
ternal consistency, test re-test reliability, responsiveness and
acceptability were explored in relevant studies relating to
the WIQ [20, 24, 26–31]. On the other hand, Spertus et al.
[30] reported Cronbach’s alpha of 0.94, indicating a possible
overlap with other domains on the measure. Two studies
[26, 30] found good evidence for the construct validity of
the WIQ; however the others [20, 24, 27–29] reported in-
consistent evidence. A single study of exercise therapy [29]
found positive evidence for the responsiveness of the scale
but mixed evidence was described by two studies [20, 30].
One study reported good evidence on internal consistency
and reliability of the AUSVIQOL in patients with PAD [18],
but there was mixed evidence for construct validity. Overall,
the study’s methodology was rated as fair. Good evidence
about the internal consistency, test-retest reliability, con-
struct validity and responsiveness of the PAQ was presented
by Spertus et al. [30]. The PAQ was developed after a review
Fig. 1 Flow diagram of study selection here
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Table 3 Table of characteristics of included studies
Author year,
country
Reported PROM (s) Clinical presentation
(Sample size)
(Ankle brachial index cut-off)
Age (years) Gender
(% males)
Timing of PROM (s)
assessment
Concomitant treatment
Chetter 1997,
UK [19]
EQ-5D
SF-36
NHP
Peripheral arterial disease
(n = 235)
68◊ 61 Baseline, week 1 NR
(NR)
Chong 2002,
UK [20]
EQ-5D
ICQ
SF-36
WIQ
Intermittent claudication
(n = 124)
71◊ 61 Baseline, week 2,
month 3
conservative medical treatment;
percutaneous transluminal angioplasty
(≤0.9)
Coyne 2003,
USA [26]
EQ-5D
PAD symptom scale,
SF-36,
WIQ (self-administered and
telephone-administered)
Peripheral arterial disease
(n = 60)
67 78 Baseline, day 4,
7, 14 and 28
NR
(<0.9, at rest)
Gulati 2009,
UK [21]
SF-36
SF-8
Peripheral arterial disease
(n = 193)
66◊ 70 Baseline; at week 2 NR
(NR)
Izquierdo-Porrera
2005, USA [27]
SF-36
WIQ
Intermittent claudication 71 91 Baseline, at week 1 exercise rehabilitation
(n = 80)
(<0.97, at rest; < 0.85, 0.85 during recovery
from exercise))
Mazari 2010,
UK [25]
EQ-5D
SF-6D
VascuQoL
Intermittent claudication
(n = 178)
70◊ 60 Baseline, at month
1, 3, 6, 12
transluminal angioplasty,
supervised exercise program,
or combined treatment
McDermott 1998,
UK [28]
WIQ Intermittent claudication
(n = 146a)
71.4 57 Baseline NR
(≤0.9, at rest)
Mehta 2006b,
UK [22]
EQ-5D
SF-36
SIPic
VascuQol
Intermittent claudication
(n =70)
70◊ 54 Baseline, at month 6 Percutaneous transluminal
angioplasty (n =47);
Conservative medical therapy (n = 23).
(NR)
Morgan 2001,
UK [23]
SF-36
VascuQol
Peripheral arterial disease
(n = 39)
67◊ 62 Baseline, at week 4 general advice, medical treatment,
angioplasty (n = 4); bypass surgery (NR)
(NR)
Regensteiner
1990, USA [29]
WIQ Intermittent claudication
(n = 26)
59 (exercise group);
64 (surgery group)
61 (control group)
NR Baseline, at week
1, 6 and 12
supervised exercise (n = 10);
bypass surgery (n = 7)
(<0.90, at rest; < 0.85, after exercise)
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Table 3 Table of characteristics of included studies (Continued)
Smith 2007,
Australia [18]
SF-36 AUSVIQOL Intermittent claudication
(n = 71)
72.8 68 Baseline, at month 1 NR
(NR)
Spertus 2004,
USA [30]
WIQ
PAQ
SF-36
Peripheral arterial disease
(n = 44)
68 55 Baseline; at week
2 and 8
Peripheral revascularization
(NR)
Tew 2013c,
UK [24]
WIQ Intermittent claudication 65 81 Baseline, within days 7
to 10 of first visit
NR
(n = 37)
(≤0.9, at rest)
Treat-Johnson
2012, USA [31]
PADQOL
POMS
SF-36
WIQ
Peripheral arterial disease
(n = 295)
67.9 75 Baseline; follow-up
(not specified)
NR
(NR)
Abbreviations: AUSVIQUOL Australian Vascular Quality of Life Index, EQ-5D EuroQoL-5D, IC intermittent claudication, ICQ Intermittent Claudication Questionnaire, M male, NR not reported, NHP Nottingham Health Profile,
PAD peripheral arterial disease, PADQOL PAD Quality of Life Questionnaire, PAQ Peripheral Artery Questionnaire, POMS Profile of Mood States, SF-36 Medical Outcomes Study 36-item Short Form, SF-6D 6-item shortened
version of SF-36, SF-8 8-item shortened version of SF-36, SIPic Sickness Impact Profile–Intermittent Claudication, VascuQoL King’s College Hospital’s Vascular Quality of Life instrument, WIQ Walking
Impairment Questionnaire
◊Indicates median age, other values relate to reported mean ages
aData presented for sub-group of study population with PAD only
bStudy also reported the validation of English version of the Claudication Scale (CLAU-S)
cStudy also reported the validation of English version of the Estimation of Ambulatory Capacity by History-Questionnaire (EACH-Q)
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Table 4 Table of items, domains, response options, scoring and administration of included outcome measures
Instrument
(number of items)
Domains (number of levels) Measure: Response
options
Scoring Mode of administration
(reported completion time, min)
Generic PROMs
SF-36 (36)
[18–23, 25–27, 30, 31]
Vitality (4), physical functioning (10), bodily pain (2),
general health perceptions (5), physical role functioning (4),
emotional role functioning (3), social role functioning (2),
mental health (5)
Likert scale: 2 to 5 Each dimension is transformed to give a score
of 0 to 100. Lower scores indicating greater
disability
Self-completed (11 min)
EQ-5D (6)
[19, 20, 22, 25, 26]
Mobility (1), self-care (1), usual activities (1), pain/discomfort (1),
and anxiety/depression (1); VAS
Likert scale: 3; VAS Preference based, values range from 0
indicating death to 1 representing
perfect health
Self-completed
SF-6D [25] Physical functioning (1), role limitation (1), social functioning (1),
pain (1), mental health (1), and vitality (1)
Likert scale: 4 to 6 Preference based 0 = dead to
1 = perfect health
Self-completed
SF-8 (8) [21] Vitality (1), physical functioning (1), bodily pain (1), general
health perceptions (1), physical role functioning (1),
emotional role functioning (1), social role functioning (1),
mental health (1)
Likert scale: 5 Each dimension is transformed to give a
score of 0–100. Lower scores indicating
greater disability
Self-completed (2.5 min)
NHP (38) [19] Physical mobility (8), pain (8), sleep (5), energy (3),
emotional reactions (9), and social isolation (5)
Dichotomous 0 (no health problems) to 100
(all the health problems)
Self-completed
POMS (65) [31] NR Likert scale: 5 NR Self-completed
Condition-specific PROMs
AUSVIQUOL
(10) [18]
General health perceptions (3), function, mobility and pain (5),
psychosocial aspects (2)
Likert scale: 5 Reponses are given points from 10 to
0 for each answer, these are summed
to give a quality of life score ranging
from 0 (poor) to 100 (excellent)
Interviewer or self-completed
(3.27 min)
ICQ (16) [20] Health related quality of life (16) Likert scale: 5 Summing scores and transforming to
a 0–100 scale
Self-completed (3.7 min)
PAQ (20) [30] Physical limitation (7), symptoms (4), quality of life (3),
social function (3), treatment satisfaction (3)
Likert scale: 5 0–100 (lower scores indicating worse
performance)
Self-completed
PADQOL (38) [31] Social relationships and interactions (9), self-concept and
feelings (7), symptoms and limitations in physical
functioning (8), fear and uncertainty (4), positive
adaptation (7)
Likert scale :5 Summed and transformed score
0 to 100%
Self-completed (5 to10 min)
SIPic (12) [22] Sickness related behaviour (12) Number of items
endorsed
0 (best quality of life) to 12
(worst quality of life)
Self-completed
WIQ (14)
[20, 24, 26–31]
Symptom severity (8)
Walking distance (7), walking speed (4), stair climbing (3)
Likert scale: 5 0 (unable to do) to 4 (no difficulty) Self-completed (6 min)
VascuQol (25)
[22, 23, 25]
Pain (4), activity (8), emotional (7), symptoms (4),
and social (2)
Likert scale: 7 1 (the worst) to7 (the best possible) Self-completed
Abbreviations: AUSVIQUOL Australian Vascular Quality of Life Index, EQ-5D EuroQol, ICQ Intermittent Claudication Questionnaire, NR not reported, NHP Nottingham Health Profile, PAD peripheral arterial disease,
PADQOL PAD Quality of Life Questionnaire, PAQ Peripheral Artery Questionnaire, POMS Profile of Mood States, SF-36 Medical Outcomes Study 36-item Short Form, SF-6D 6-item shortened version of SF-36, SF-8 8-item
shortened version of SF-36, SIPic Sickness Impact Profile–Intermittent Claudication, VAS visual analogue scale, VascuQoL King’s College Hospital’s Vascular Quality of Life instrument, WIQ Walking
Impairment Questionnaire
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Table 5 Summary of the psychometric properties of patient-reported outcome measures in patients with peripheral arterial disease
Internal consistency Test-retest Content validity Construct validity Responsiveness Floor/ ceiling Acceptability
Generic PROMs
EQ-5D
Chetter 1997 [19] 0 ? 0 −/+ −/+ 0 0
Chong 2002 [20] 0 0 0 ? −/+ 0 0
Coyne 2003 [26] 0 0 0 −/+ 0 0 0
Mazari 2010 [25] 0 0 0 + −/+ 0 0
Mehta 2006 [22] 0 0 0 ? + 0 0
NHP
Chetter 1997 [19] 0 ? 0 −/+ + −/+ 0
POMS
Treat-Jacobson 2012 [31] 0 0 0 −/+ 0 0 0
SF-6D [25] 0 0 0 −/+ + 0. 0
SF-8
Gulati 2009 [21] 0 ? 0 + −/+ 0 0
SF-36
Chetter 1997 [19] 0 ? 0 −/+ −/+ −/+ 0
Chong 2002 [20] 0 0 0 + −/+ 0 0
Coyne 2003 [26] 0 0 0 −/+ 0 0 0
Gulati 2009 [21] 0 ? 0 + −/+ 0 0
Izquierdo-Porrera 2005 [27] 0 0 0 −/+ 0 0 0
Mazari 2010 [25] 0 0 0 −/+ + 0 0
Mehta 2006 [22] 0 0 0 + −/+ 0 0
Morgan 2001 [23] 0 0 0 + −/+ 0 0
Smith 2007 [18] − + 0 −/+ 0 0 ?
Spertus 2003 [30] + + 0 + −/+ 0 0
Treat-Jacobson 2012 [31] 0 0 0 −/+ 0 0 0
Condition-specific PROMs
AUSVIQUOL
Smith 2007 [18] + + 0 −/+ 0 0 ?
ICQ
Chong 2002 [20] −/+ + + −/+ + ? +
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Table 5 Summary of the psychometric properties of patient-reported outcome measures in patients with peripheral arterial disease (Continued)
PADQOL
Treat-Jacobson 2012 [31] + 0 + −/+ 0 0 0
PAQ
Spertus 2003 [30] + + + + + 0 0
SIPic
Mehta 2006 [22] 0 0 0 + −/+ 0 0
WIQ
Chong 2002 [20] 0 0 0 −/+ −/+ 0 0
Coyne 2003 [26] −/+ −/+ 0 + 0 0 0
Izquierdo-Porrera 2005 [27] 0 0 0 −/+ 0 0 0
McDermott 1998 [28] 0 0 0 −/+ 0 0 0
Regensteiner 1990 [29] 0 ? 0 −/+ + 0 0
Spertus 2003 [30] −/+ + 0 + −/+ 0 0
Tew 2013 [24] 0 0 0 −/+ 0 0 +
Treat-Jacobson 2012 [31] 0 0 0 −/+ 0 0 0
VascuQoL
Mazari 2010 [25] 0 0 0 + + 0 0
Mehta 2006 [22] 0 0 0 + −/+ 0 0
Morgan 2001 [23] + + + + + 0 0
Psychometric and operational criteria
0 Not reported (no evaluation completed)
- Evidence not in favour
−/+ Weak evidence in favour
+ Evidence in favour
? Methodology questionable
N.B. Blank criterion validity excluded from the table.
NB Criterion validity recorded as zero across studies therefore results are not displayed
Abbreviations: AUSVIQUOL Australian Vascular Quality of Life Index, Q Questionnaire, EQ-5D EuroQol, ICQ Intermittent Claudication Questionnaire, NHP Nottingham Health Profile, PAD peripheral arterial disease,
PADQOL PAD Quality of Life Questionnaire, PAQ Peripheral Artery Questionnaire, POMS Profile of Mood States, SF-36 Medical Outcomes Study 36-item Short Form, SF-6D 6-item shortened version of SF-36, SF-8 8-item
shortened version of SF-36, SIPic Sickness Impact-Intermittent Claudication, VascuQoL King’s College Hospital’s Vascular Quality of Life instrument, WIQ Walking Impairment Questionnaire
Poku
et
al.H
ealth
and
Q
uality
of
Life
O
utcom
es
 (2016) 14:161 
Page
10
of
14
of the medical literature, examination of the available
measures, focus groups with clinicians and unstructured in-
terviews with patients suggesting positive content validity.
However, the methodology of the study was found to be
poor. Good evidence was observed for the internal
consistency and content validity of the PADQOL in one
study [31]. Generally, the reported methodology was rated
as good, but construct validity was found to have mixed evi-
dence due to the lack of prior hypotheses [31]. The meas-
urement properties of the ICQ were examined in a study
[20] that reported a Cronbach’s alpha of 0.94, indicating high
correlation between items. However, positive results were
found for the test-retest reliability, content validity and re-
sponsiveness. In this study, mixed evidence was found for
the construct validity due to a lack of a clear hypothesis.
The methodology to assess these criteria was generally good,
although the responsiveness received only a fair rating [20].
The SIPIC was evaluated with patients with lifestyle-limiting
claudication [22]. Good evidence was found for construct
validity and mixed evidence for responsiveness.
Two studies reported the psychometric assessment of
modified PROM instruments. These were the modified
telephone-administered WIQ [26] and the SF-8, an
abridged version of the SF-36 [21]. Both the originally
developed telephone-administered WIQ and the modi-
fied self-administered version were reported to be valid
and reliable for objectively assessing community walking.
The authors proposed that self-administration reduced
the WIQ completion time, from five minutes to one mi-
nute. [26].
Discussion
Fourteen studies assessing the psychometric properties of 13
newly-developed and existing PROMs in patients with symp-
tomatic PAD, regardless of specific presentation were in-
cluded in this review. Substantial variations in the reporting
of clinical presentation of PAD, management strategies and
administration of instruments were noted. Evidence of super-
iority in the psychometric performance of a single PROM
could not be established. This may be a reflection of the dif-
ferences in patient characteristics and study methodology ra-
ther than the appropriateness of the instruments themselves.
Clinicians and researchers have a wide variety of PROMs
to consider for patients with PAD. The review included gen-
eric PROMs as well as PROMs that covered PAD-related
symptoms e.g. VascuQoL (pain); WIQ (walking speed)
and PADQoL (symptoms and limitations of function fear
and anxiety). Of the generic PROMs evaluated, the SF-36
showed the most complete and positive evidence in favour
of use in a PAD population. The domains of the SF-36 pro-
vided a broader measure than the PAD-specific PROMs.
This instrument included further questioning on the do-
mains of pain and mobility, but also on specific fears. How-
ever, related studies were of mixed methodological quality.
The review showed that using modified versions of the
WIQ and SF-36 provided useful PROMs data in terms of
test re-test reliability, construct validity and responsiveness.
Nonetheless, adopting these instruments in practice re-
quires more consideration of their appropriateness
considering the extent of variation in the available literature.
Although the WIQ provides a good condition-specific
measure of mobility relevant to IC, it does not include QOL
measures relating to PAD, in general. The VascuQol was
found to have good internal consistency, test-retest reliabil-
ity, construct validity and responsiveness as well as good
content validity for measuring QOL of patients with PAD.
Several factors may influence the choice of a PROM.
Careful consideration is required regarding whether a com-
bination of measures should be recommended for use in
symptomatic patients or whether a single PROM covering
different aspects of health would be more appropriate for
obtaining the patient’s perspective on treatment and general
health. Furthermore, patients’ characteristics (stage of PAD,
treatment, co-existing conditions) must be carefully consid-
ered. Included studies dealt with patients with symptomatic
PAD and more research is needed to understand the
relevance of using PROMs in those with asymptomatic
PAD. This is of particular importance because PAD repre-
sents a continuum of clinical presentations. A decision about
whether or not to use a single PROM or set of PROMs in
practice should be at the discretion of clinicians or re-
searchers. One key area of attention, however, should include
the burden of administering a questionnaire (including
format, setting, time for completion). In the study by Coyne
et al. [26], the authors reported that the modified (self-ad-
ministered) WIQ was reliable and valid when compared to
the version administered by an interviewer over the tele-
phone [26]. However, recent evidence suggests that the
number of errors occurring during self-completion of the
WIQ was unacceptably high [33, 34] and this will have im-
plications for administering a tool as well as interpreting the
findings of the self-completed PROMs. Furthermore, limited
or unclear reporting makes inferences about completion
time reasonably challenging. Methods for calculating com-
pletion time, additional support provided and reading level
of participants were often not reported within included
studies.
Whereas it is not possible to single out one measure for
recommendation, it is evident that condition-specific mea-
sures were the only tools with reported content validity re-
lated to PAD. Based on the findings of this review, the PAQ
and VascuQoL would seem to be appropriate condition-
specific tools for predominantly English speakers. The ICQ
could be selected as a tool of choice for patients with inter-
mittent claudication, only. Measurements of PROMs must
be practical, acceptable and reliable. Therefore, qualitative
evidence based on patients’ views and experiences will also
be valuable. Additionally, clinical trials which incorporate
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PROMs as outcome measures may be used to assess the
performance of relevant PROMs but this is beyond the
scope of this paper. Collectively, such evidence will help in
selecting PROMs for use in routine practice.
Clear and complete reporting of validation studies is es-
sential. The quality of reporting in the included studies was
often, inadequate or ambiguous. For example, patient se-
lection was not presented in a meaningful way in most
studies. Whilst some studies explicitly stated that patients
with more severe forms of PAD were excluded, a few stud-
ies did not provide information to identify any stratification
of the study population. The ankle-brachial index (ABI)
cut-offs for selecting patients in included studies were
often not reported or varied across studies.
In this review, the methodological quality of the studies
was evaluated on the basis of the COSMIN criteria. How-
ever, this checklist is time-consuming to apply and although
it provides a method for assessing the quality of the studies,
it has been criticised for being difficult to apply in a consist-
ent manner [14]. The current review, similar to the study
by Morris et al. (2014) [14], also demonstrated that many
of the included studies had not reported on how missing
information was handled. The approach used for handling
missing data is a key criterion for the COSMIN checklist.
Subsequently, most of the studies were rated low in terms
of quality. Another systematic review of PROMs in patients
with IC found that the methodological quality of most
studies ranged from poor to fair [35]. Our review supports
the findings of the review by Conijn et al. [35] confirming
the need for better quality studies of PROMs.
Strengths and Limitations of the review
Comprehensive and iterative literature searching was
undertaken to improve the retrieval of relevant studies.
Our efforts improved article retrieval because more than
half of included studies were not identifiable as validation
studies by titles only. This review identified PROMs for
patients with IC and other stages of PAD. It is possible
that the differences in clinical states may have influenced
the findings of psychometric assessments. Previous re-
views have been much more restricted in their scope and
limited in the range of sources searched. By broadening
the scope of the population of interest, this study has also
highlighted the evidence gap regarding validation of
PROMs in patients with more severe forms of PAD or
more specifically, patients with amputation due to PAD.
In an effort to identify suitable PROMs for patients re-
ceiving care for PAD within the NHS in England, we ex-
cluded non-English populations or PROMs developed or
available in other languages other than English. As a result,
potentially informative data, for example, from validation of
non-eligible PROMs [36–38] was not included in this study.
The impact of excluding non-English populations or
PROMs in this review is unclear. However, this approach
was reasonable because of challenges with linguistic valid-
ation and cultural adaptation of outcome measures [9]. Lit-
erature searches were updated in January 2015 so more
recent relevant studies may have been missed.
Implications for practice and future research
Due to heterogeneity and methodological quality of studies
included in this review, no single PROM can be recom-
mended for use. It is recommended that clinicians and re-
searchers take into account the factors related to the burden
of administration, patient characteristics and treatment
strategies when selecting appropriate PROMs. Any suitable
instrument should aim to cover all relevant domains of
interest to patients.
The standardisation of study methodology and reporting
must be encouraged with the view to improve interpret-
ation of findings of validation studies. Existing minimum
standards for PROMs [39] provides useful guidelines in
designing, choosing and validating PROMs. The latter can
be used alongside the COSMIN checklist to design and
reporting validation studies. The next stage of our research
is to complete a qualitative review to obtain patient’s views
about factors that significantly affect their daily functioning
and QoL whilst living with PAD and a review of PROMs as
outcomes in randomised studies. It is anticipated that the
evidence created will inform the selection or development
of a new tool to obtain PROMs in patients with PAD at-
tending clinics within the NHS, England.
Conclusions
This review provides an in-depth summary of PROMs
evaluated in English-speaking patients with symptomatic
PAD. No study provided evidence of a full psychometric
evaluation in the patient population of interest. The con-
sideration of diverse factors will help to identify a suit-
able PROM or combination of measures for clinical and
health care decision-making. Additionally, standardised
methodologies will help to substantially improve the
interpretation of findings from validation studies.
Additional files
Additional file 1: Search strategies (DOCX 28 kb)
Additional file 2: Table S1. Methodological assessment of quality of
each PROM by study using the COSMIN criteria (DOCX 75 kb)
Abbreviations
AUSVIQUOL: Australian Vascular Quality of Life Index; CLAU-S: Claudication Scale;
CLI: Critical limb ischaemia; COSMIN: Consensus-based Standards for the selection
of health Measurement INstruments; EACH-Q: Estimation of Ambulatory Capacity
by History-Questionnaire; EMBASE: Excerpta Medica dataBASE; ePAQ: Electronic
personal assessment questionnaire; EQ-5D: EuroQoL-5D; IC: Intermittent
claudication; ICQ: Intermittent Claudication Questionnaire; MeSH: Medical Subject
Heading; NHP: Nottingham Health Profile; NHS: National Health Service; NR: Not
reported; PAD: Peripheral arterial disease; PADQOL: PAD Quality of Life
Questionnaire; PAQ: Peripheral Artery Questionnaire; POMS: Profile of Mood States;
Poku et al. Health and Quality of Life Outcomes  (2016) 14:161 Page 12 of 14
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis;
PROM: Patient-reported outcome measure; PROQOLID: Patient-Reported Outcome
and Quality of Life Instruments database; QoL: Quality of life; SF-36: Medical
Outcomes Study 36-item short form health survey; SF-6D: 6-item shortened version
of SF-36; SF-8D: 8-item shortened version of SF-36; SG: Standard gamble;
SIPic: Sickness Impact Profile-Intermittent Claudication; TTO: Time trade-off;
VAS: Visual analogue scale; VascuQoL: King’s College Hospital’s Vascular Quality of
Life instrument; WIQ: Walking Impairment Questionnaire
Acknowledgements
We are grateful to Emma Wilson and Kath Wilson for providing
administrative support whilst designing and undertaking the study.
Funding
This research was funded by the National Institute for Health Research
(NIHR)—The Design, Development, Commissioning and Evaluation of Patient
Focused Vascular Services (RP-PG-1210-12009). The funder had no role in the
study design, data collection, data analysis, data interpretation or writing of this
article. All authors who contributed to this research received funding from the
above-mentioned grant (RP-PG-1210-12009).
Availability of data and materials
The datasets supporting the conclusions of this article are included within
the article and its additional files.
Authors’ contributions
EP was responsible for the conception and design of the study, data
collection, analysis and interpretation of findings, drafting, critically reviewing
and revising intellectual content of the manuscript and also approved the
final version. RD was responsible for the conception and design of the study,
data collection, analysis and interpretation of findings, drafting, critically
reviewing and revising intellectual content of the manuscript and also
approved the final version. AK contributed to data collection, analysis and
interpretation of findings and also drafted, critically reviewed and revised
intellectual content of the manuscript and approved the final version. ME
was responsible for the conception and design of the study, data collection,
critically reviewing intellectual content of the manuscript and approved the
final version. PP participated in the conception and design of the study, data
collection, critically reviewing intellectual content of the manuscript and
approved the final version. HBW participated in the conception and design
of the study, data collection, critically reviewed and revised intellectual
content and approved the final version of the manuscript. SP participated in
the conception and design of the study, data collection, critically reviewed
and revised intellectual content and also approved the final version of the
manuscript. GW participated in the conception and design of the study, data
collection, critically reviewed and revised intellectual content and approved
the final version of the manuscript. EK participated in the conception and
design of the study, critically reviewed and revised intellectual content and
approved the final version of the manuscript. JM participated in the
conception and design of the study, critically reviewed and revised
intellectual content and approved the final version of the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
This research is a systematic review which was based on published data. It
does not contain information obtained directly from individual patients.
Therefore, consent for publication is not applicable.
Ethics approval and consent to participate
Not applicable.
Disclaimer
This paper presents independent research funded by the National Institute
for Health Research (NIHR) under the Programme Grants for Applied
Research programme: The Design, Development, Commissioning and
Evaluation of Patient Focused Vascular Services (RP-PG-1210-12009).
The views expressed are those of the authors and not necessarily those
of the NHS, the NIHR or the Department of Health.
Author details
1School of Health and Related Research, University of Sheffield, Sheffield S1
4DA, UK. 2University of Alberta, 116 St & 85 Ave, Edmonton T6G 2R3, AB,
Canada. 3Leeds Beckett University, School of Social Sciences, City Campus,
Leeds LS1 3HE, UK.
Received: 27 May 2016 Accepted: 12 November 2016
References
1. Dawson J, Doll H, Fitzpatrick R, Jenkinson C, Carr A. The routine use of
patient reported outcome measures in healthcare settings. Br Med J. 2010;
340:c186.
2. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome
measures for use in clinical trials. Health technol assess. 1998;2(14):1–74.
3. Health, Social Care Information. Finalised Patient Reported Outcome
Measures (PROMs) In England: April 2011 to March 2012. 2014. Available at
http://www.content.digital.nhs.uk/catalogue/PUB11359/final-proms-eng-
apr11-mar12-fin-report-v2.pdf. Accessed 15 Nov 2016.
4. Regensteiner JG, Hiatt WR. Current medical therapies for patients with
peripheral arterial disease: a critical review. Am J Med. 2002;112(1):49–57.
5. Hiatt WR. Medical treatment of peripheral arterial disease and claudication.
N Engl J Med. 2001;344(21):1608–21.
6. Macefield RC, Jacobs M, Korfage IJ, Nicklin J, Whistance RN, Brookes ST,
Sprangers MA, Blazeby JM. Developing core outcomes sets: methods for
identifying and including patient-reported outcomes (PROs). Trials. 2014;15:49.
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke
M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate healthcare
interventions: explanation and elaboration. BMJ. 2009;339:b2700.
8. Jenkinson C, Gibbons E, Fitzpatrick R. A structured review of patient-
reported outcome measures in relation to stroke, Report for the UK
Department of Health. 2009.
9. Schellingerhout JM, Heymans MW, Verhagen AP, de Vet HC, Koes BW,
Terwee CB. Measurement properties of translated versions of neck-specific
questionnaires: a systematic review. BMC Med Res Methodol. 2011;11:87.
10. Emery MP, Perrier LL, Acquadro C. Patient-reported outcome and quality of
life instruments database (PROQOLID): frequently asked questions. Health
Qual Life Outcomes. 2005;3:12.
11. McKenna SP. Measuring patient-reported outcomes: moving beyond
misplaced common sense to hard science. BMC Med. 2011;9:86.
12. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter
LM, de Vet HC. The COSMIN checklist for assessing the methodological
quality of studies on measurement properties of health status measurement
instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49.
13. Terwee CB, Mokkink LB, Knol DL, Ostelo RW, Bouter LM, de Vet HC. Rating
the methodological quality in systematic reviews of studies on
measurement properties: a scoring system for the COSMIN checklist. Qual
Life Res. 2012;21(4):651–7.
14. Morris C, Janssens A, Allard A, Thompson CJ, Shilling V, Tomlinson R,
Williams J, Fellowes A, Rogers M, Allen K et al. Informing the NHS Outcomes
Framework: evaluating meaningful health outcomes for children with
neurodisability using multiple methods including systematic review,
qualitative research, Delphi survey and consensus meeting. Health Serv
Deliv Res. 2014;2(15).
15. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter
LM, de Vet HC. Quality criteria were proposed for measurement properties of
health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42.
16. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier PP.
The community-acquired pneumonia symptom questionnaire: a new,
patient-based outcome measure to evaluate symptoms in patients with
community-acquired pneumonia. Chest. 2002;122(3):920–9.
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences, Erlbaum.
Secondth ed. 1988.
18. Smith MJ, Borchard KL, Hinton E, Scott AR. The Australian Vascular Quality of
Life Index (AUSVIQUOL): an improved clinical quality of life tool for
peripheral vascular disease. Eur J Vasc Endovasc Surg. 2007;34(2):199–205.
19. Chetter IC, Spark JI, Dolan P, Scott DJ, Kester RC. Quality of life analysis in
patients with lower limb ischaemia: suggestions for European
standardisation. Eur J Vasc Endovasc Surg. 1997;13(6):597–604.
Poku et al. Health and Quality of Life Outcomes  (2016) 14:161 Page 13 of 14
20. Chong PFS, Garratt AM, Golledge J, Greenhalgh RM, Davies AH. The
intermittent claudication questionnaire: a patient-assessed condition-specific
health outcome measure. J Vasc Surg. 2002;36(4):764–71.
21. Gulati S, Coughlin PA, Hatfield J, Chetter IC. Quality of life in patients with
lower limb ischemia; revised suggestions for analysis. J Vasc Surg. 2009;
49(1):122–6.
22. Mehta T, Venkata SA, Chetter I, McCollum P. Assessing the validity and
responsiveness of disease-specific quality of life instruments in intermittent
claudication. Eur J Vasc Endovasc Surg. 2006;31(1):46–52.
23. Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the Vascular Quality
of Life Questionnaire: a new disease-specific quality of life measure for use
in lower limb ischemia. J Vasc Surg. 2001;33(4):679–87.
24. Tew G, Copeland R, Le Faucheur A, Gernigon M, Nawaz S, Abraham P.
Feasibility and validity of self-reported walking capacity in patients with
intermittent claudication. J Vasc Surg. 2013;57(5):1227–34.
25. Mazari FAK, Carradice D, Rahman MN, Khan JA, Mockford K, Mehta T,
McCollum PT, Chetter IC. An analysis of relationship between quality of life
indices and clinical improvement following intervention in patients with
intermittent claudication due to femoropopliteal disease. J Vasc Surg. 2010;
52(1):77–84.
26. Coyne KS, Margolis MK, Gilchrist KA, Grandy SP, Hiatt WR, Ratchford A,
Revicki DA, Weintraub WS, Regensteiner JG. Evaluating effects of method of
administration on Walking Impairment Questionnaire. J Vasc Surg. 2003;
38(2):296–304.
27. Izquierdo-Porrera AM, Gardner AW, Bradham DD, Montgomery PS, Sorkin
JD, Powell CC, Katzel LI. Relationship between objective measures of
peripheral arterial disease severity to self-reported quality of life in older
adults with intermittent claudication. J Vasc Surg. 2005;41(4):625–30.
28. McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P.
Measurement of walking endurance and walking velocity with
questionnaire: validation of the walking impairment questionnaire in men
and women with peripheral arterial disease. J Vasc Surg. 1998;28(6):1072–81.
29. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking
impairment by questionnaire in patients with peripheral arterial disease. Eur
J Vasc Endovasc Surg. 1990;2:142–52.
30. Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery
questionnaire: a new disease-specific health status measure for patients
with peripheral arterial disease. Am Heart J. 2004;147(2):301–8.
31. Treat-Jacobson D, Lindquist RA, Witt DR, Kirk LN, Schorr EN, Bronas UG,
Davey CS, Regensteiner JG. The PADQOL: development and validation of a
PAD-specific quality of life questionnaire. Vasc Med. 2012;17(6):405–15.
32. Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS. Patient-
reported outcomes: instrument development and selection issues. Value
Health. 2007;10 Suppl 2:S86–93.
33. Mahe G, Ouedraogo N, Vasseur M, Faligant C, Saidi K, Leftheriotis G,
Abraham P. Limitations of self-reported estimates of functional capacity
using the Walking Impairment Questionnaire. Eur J Vasc Endovasc Surg.
2011;41(1):104–9.
34. Mahe G, Ouedraogo N, Marchand J, Vielle B, Picquet J, Leftheriotis G,
Abraham P. Self-reported estimation of usual walking speed improves the
performance of questionnaires estimating walking capacity in patients with
vascular-type claudication. J Vasc Surg. 2011;54(5):1360–5.
35. Conijn AP, Jens S, Terwee CB, Breek JC, Koelemay MJ. Assessing the quality
of available patient reported outcome measures for intermittent
claudication: a systematic review using the COSMIN checklist. Eur J Vasc
Endovasc Surg. 2015;49(3):316–34.
36. Ouedraogo N, Mahe G, Marchand J, Saidi K, Leftheriotis G, Abraham P, et al.
Validation of a new simple questionnaire to “estimate ambulation capacity by
history” (EACH) in patients with claudication. J Vasc Surg. 2011;54(1):133–8.
37. Spengel FA, Lehert P, Dietze S. A statistical consideration of CLAU-S: a
disease specific questionnaire for the assessment of quality of life in
patients with intermittent claudication. VASA. 1998;27:253.
38. Wann-Hansson C, Hallberg IR, Risberg B, Klevsgard R. A comparison of the
Nottingham Health Profile and Short Form 36 Health Survey in patients
with chronic lower limb ischaemia in a longitudinal perspective. Health
Qual Life Outcomes. 2004;2:9.
39. Reeve BB, Wyrwich KW, Wu AW, Terwee CB, Synder CF, Schwartz C, Revicki
DD, Monipour CM, McLeod LD, Lyons JC. ISOQOL recommends minimum
standards for patient-reported outcome measures used in patient-centered
outcomes and comparative effectiveness research. Qual Life Res. 2013;22:
1889–905.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Poku et al. Health and Quality of Life Outcomes  (2016) 14:161 Page 14 of 14
